WeVote
Log In

Bill

Bill

SF 1302

Coverage of cancer imaging and clinical genetic testing requirement

2025-2026 Regular Session Introduced by Liz Boldon and 3 co-sponsors

Minnesota bill requires insurers to cover cancer imaging and genetic testing without prior authorization, removing administrative delays in diagnostic screening access.

Comm report: To pass as amended and re-refer to Health and Human Services
#healthandhealthdepartment #insurance-health
0
WeVote Research Nonpartisan
Bill Summary · SF 1302

Legislative bill overview

SF 1302 requires health insurance plans in Minnesota to cover cancer imaging procedures and clinical genetic testing without prior authorization requirements. The bill aims to streamline access to diagnostic and preventive cancer screening by removing administrative barriers that currently delay or prevent coverage of these services.

Why is this important

Cancer detection relies heavily on timely imaging and genetic testing to identify risk factors and early-stage disease. Prior authorization delays can postpone diagnosis and treatment, potentially affecting outcomes. This bill removes insurance company gatekeeping for these specific services, directly impacting how quickly Minnesotans can access cancer-related diagnostic care.

Potential points of contention

  • Cost concerns: Health insurers may argue that mandatory coverage without prior authorization increases overall healthcare costs, which could be passed to consumers through higher premiums
  • Definition scope: The bill's specific language on which imaging types and genetic tests qualify could be debated—overly broad definitions might increase costs, while narrow ones could limit access
  • Prior authorization necessity: Insurance industry may contend that prior authorization prevents unnecessary testing and protects against overutilization, particularly for expensive genetic panels or advanced imaging

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.